{{Rsnum
|rsid=959091
|Gene=ELAVL2
|Chromosome=9
|position=23775451
|Orientation=plus
|GMAF=0.1768
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Gene_s=ELAVL2
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 90.2 | 9.8 | 0.0
| HCB | 51.5 | 41.0 | 7.5
| JPT | 55.0 | 41.4 | 3.6
| YRI | 70.5 | 26.0 | 3.4
| ASW | 78.9 | 21.1 | 0.0
| CHB | 51.5 | 41.0 | 7.5
| CHD | 49.5 | 40.4 | 10.1
| GIH | 74.7 | 22.2 | 3.0
| LWK | 75.0 | 24.1 | 0.9
| MEX | 40.4 | 42.1 | 17.5
| MKK | 73.5 | 25.2 | 1.3
| TSI | 81.0 | 16.0 | 3.0
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs959091
|Name_s=
|Gene_s=ELAVL2
|Feature=
|Evidence=PubMed ID:19176441
|Annotation=This variant is associated with end-of-induction minimal risidual disease (MRD) in childhood acute lymphoblastic leukemia (ALL) from 2 independent cohorts (GWAS result). Risk Allele: G, MAF= 0.12, combined P value= 6.75E-04.
|Drugs=
|Drug Classes=
|Diseases=Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma
|Curation Level=Curated
|PharmGKB Accession ID=PA162470249
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs959091
|overall_frequency_n=19
|overall_frequency_d=128
|overall_frequency=0.148438
|n_genomes=19
|n_genomes_annotated=0
|n_haplomes=20
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | FTDNA}}
{{on chip | Illumina Human 1M}}